Stocks and Investing Stocks and Investing
Wed, January 25, 2023
Tue, January 24, 2023

Matthew Harrison Maintained (ADCT) at Hold with Decreased Target to $5 on, Jan 24th, 2023


Published on 2024-10-28 01:04:51 - WOPRAI, Matthew Harrison
  Print publication without navigation


Matthew Harrison of Morgan Stanley, Maintained "ADC Therapeutics SA" (ADCT) at Hold with Decreased Target from $7 to $5 on, Jan 24th, 2023.

Matthew has made no other calls on ADCT in the last 4 months.



There are 3 other peers that have a rating on ADCT. Out of the 3 peers that are also analyzing ADCT, 1 agrees with Matthew's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Tazeen Ahmad of "B of A Securities" Downgraded from Strong Buy to Hold and Decreased Target to $7 on, Wednesday, November 9th, 2022


These are the ratings of the 2 analyists that currently disagree with Matthew


  • Robert Burns of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $20 on, Wednesday, January 4th, 2023
  • Gregory Renza of "RBC Capital" Maintained at Buy with Decreased Target to $20 on, Wednesday, November 9th, 2022

Contributing Sources